La vendita allo scoperto per Nuburu dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Nuburu. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Nuburu (AMEX:BURU) Azioni, Report sulle vendite allo scoperto

Nuburu

Nuburu Inc is a leading innovator in high-power, high-brightness blue laser technology that is focused on bringing breakthrough improvements to multiple markets, including e-mobility, healthcare, and consumer electronics via a broad range of high-value applications that include welding and 3D printing. It is currently shipping blue laser systems for applications such as EV batteries, large screen displays, and cell phone components.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

BURU

FLNC

Esploriamo le migliori opportunità di investimento in azioni industriali, che potrebbero offrire rendimenti significativi.

3 titoli industriali che potrebbero salvare il tuo portafoglio questo mese

Equities

Market Summary

Movers & Shakers

Economics

Federal Reserve

General

ADBE

AMPG

CIEN

DBVT

MAGS

NDSN

Giovedì i future azionari statunitensi sono scesi negli scambi pre-market, dopo aver toccato mercoledì nuovi massimi. I future dei quattro principali indici azionari erano in ribasso. 



I dati sull&#39;inflazione di

Wall Street Pronto ad Aprire al Ribasso un Giorno Dopo il Record di Chiusura del Nasdaq Sopra i 20.000 Punti: Esperto Segnala &#39;Deterioramento Sotto la Superficie&#39; con 117 Azioni S&amp;P 500 a Nuovi Minimi Mensili

Nuburu Inc

Nuburu Inc Class A

Buru Energy Ltd

Barclays analyst Alex Scott maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and lowers the price target from $95 to $88.

Price Target

Analyst Ratings

Barclays Maintains Overweight on MetLife, Lowers Price Target to $88

WIIM

CART

Maplebear shares are trading higher after JMP Securities reiterated a Market Outperform rating and maintained a $55 price target.

Barclays analyst Alex Scott maintains Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) with a Equal-Weight and raises the price target from $246 to $249.

Barclays Maintains Equal-Weight on Marsh & McLennan Cos, Raises Price Target to $249

Barclays analyst Alex Scott maintains Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) with a Equal-Weight and lowers the price target from C$49 to C$45.

TSX:MFC

Barclays Maintains Equal-Weight on Manulife Financial, Lowers Price Target to C$45

Barclays analyst Alex Scott maintains Jackson Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JXN#NYSE">JXN</a>) with a Overweight and lowers the price target from $118 to $106.

Barclays Maintains Overweight on Jackson Finl, Lowers Price Target to $106

Barclays analyst Alex Scott maintains Fidelis Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIHL#NYSE">FIHL</a>) with a Equal-Weight and lowers the price target from $18 to $16.

FIHL

Barclays Maintains Equal-Weight on Fidelis Insurance Hldgs, Lowers Price Target to $16

Barclays analyst Mark Devries maintains F&amp;G Annuities &amp; Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FG#NYSE">FG</a>) with a Equal-Weight and lowers the price target from $47 to $41.

Barclays Maintains Equal-Weight on F&G Annuities & Life, Lowers Price Target to $41

Chamath Palihapitiya believes President Donald Trump's tariff push could reshape global economics — and he's not being subtle about it.
In a series of recent posts and comments, the venture capitalist and former Facebook executive said Trump should &#8220;hold the line&#8221; on tariffs, despite the market chaos. &#8220;Volatility aside — which matters to traders more than it should matter to long-term investors — the tariff gambit is working,&#8221; Palihapitiya <a href="https://x.com/chamath/status/1909260659180650853">posted</a> on X.
Don't Miss:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
<h2 class="wp-block-heading">Bretton Woods 2.0</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is your daily reminder that we are only a few days into tariffs. There is an enormous opportunity here to write Bretton Woods 2.0 &#8211; The Mar-a-Lago Accords. Time favors Trump. The longer he takes, the more he will get.
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1908901234049982498?ref_src=twsrc%5Etfw">April 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He sees this moment as a rare opening to reset the global trade system, comparing it to the landmark 1944 Bretton Woods Agreement. &#8220;There is an enormous opportunity here to write Bretton Woods 2.0 — The Mar-a-Lago Accords,&#8221; he wrote in another <a href="https://x.com/chamath/status/1908901234049982498">post</a>. &#8220;Time favors Trump. The longer he takes, the more he will get.&#8221;
<h2 class="wp-block-heading">Markets Are Shaking, But Trump Isn't</h2>
Global markets <a href="https://www.benzinga.com/25/04/44663034/asia-in-freefall-hang-seng-posts-worst-drop-since-1997-europe-market-tumbles-oil-slips-gold-eases-global-markets-today-while-us-slept">have been reeling</a> since Trump announced sweeping tariffs on April 2. U.S. stock indexes tumbled last week, with the Nasdaq falling into bear market territory. <a href="https://www.benzinga.com/markets/equities/25/04/44660335/chamath-palihapitiya-warns-fed-and-trump-may-no-longer-rescue-markets-as-bottom-50-of-americans-have-zero-interest-in-stocks">Futures extended the slide</a> Sunday night, and Asian markets took a beating as well. Bitcoin also dropped nearly 6%.
Still, Trump seems unfazed. Speaking to reporters aboard Air Force One, he <a href="https://www.youtube.com/watch?v=6hU836SeK_I">said</a>, &#8220;Sometimes you have to take medicine to fix something,&#8221; and reiterated he won't back down until other countries even out their trade with the U.S.
&#8220;They're dying to make a deal,&#8221; Trump said of other nations, adding, &#8220;We're not going to have deficits with your country&#8230; We're going to have surpluses or, at worst, going to be breaking even.&#8221;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">The Bottom Half Has No Skin in the Game</h2>
Palihapitiya also pointed out a major reason political support for market rescues may be fading. &#8220;The top 10% of American households own 88% of the total equities owned by American households,&#8221; he <a href="https://x.com/chamath/status/1908375732788908422">wrote</a>. &#8220;The next 40% of households own 12%. This means the bottom 50% of Americans have ZERO interest in the stock market, are likely in debt and, simply, just want to do better.&#8221;
That's why, <a href="https://www.benzinga.com/markets/equities/25/04/44660335/chamath-palihapitiya-warns-fed-and-trump-may-no-longer-rescue-markets-as-bottom-50-of-americans-have-zero-interest-in-stocks">he argues</a>, traditional stock market bailouts like a &#8220;Fed put&#8221; or &#8220;White House put&#8221; might no longer be politically viable. &#8220;This may be a moment to hold a radical new view which is that the put is off the table,&#8221; he wrote.
However, some pointed out in the comments that almost every American has &#8220;skin in the game.&#8221; As one X user <a href="https://x.com/Sarcastic_Canuk/status/1908432662269682003">said</a>, &#8220;You may not own stocks, but your company is probably listed. If the market crashes, so does your employer.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The market is forecasting a recession you dummy. The bottom 50% who don&#39;t own stocks will be the ones unemployed and lining up at soup kitchens.
&mdash; Art of the Deal Capital (@TheRealDavey2) <a href="https://twitter.com/TheRealDavey2/status/1908388946125742514?ref_src=twsrc%5Etfw">April 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another added, &#8220;The bottom 50% who don&#8217;t own stocks will be the ones unemployed and lining up at soup kitchens.&#8221;
See Also: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
<h2 class="wp-block-heading">World Responds as Tariffs Take Hold</h2>
White House officials claim that more than 50 countries have reached out to negotiate. Some U.S. allies, like Israel and Vietnam, are already pushing for better terms. Others, like Italy, have criticized the move but signaled openness to discussions.
Some Republicans in Congress are working on a bill to rein in presidential tariff powers. Rep. Don Bacon (R-NE) said the executive branch shouldn't have unchecked authority, saying it &#8220;was a mistake.&#8221;
Trump's own economic adviser, Elon Musk, said he preferred a zero-tariff world. That didn't go over well with the White House. Trade adviser Peter Navarro responded, &#8220;Elon sells cars&#8230; He's simply protecting his own interest.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">With Shares Starting at Just $1.52, This Could be Your Chance to Invest in the Future of Healthcare.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Chamath Palihapitiya Says 'Time Favors Trump,' Sees A Big Opportunity To Rewrite Global Economics With 'The Mar-A-Lago Accords'

Barclays analyst Alex Scott maintains Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) with a Overweight and lowers the price target from $470 to $394.

Barclays Maintains Overweight on Everest Group, Lowers Price Target to $394

BABA

BIDU

XPEV

Shares of Chinese stocks are trading higher. Chinese stocks may be volatile amid the escalation of US-china trade tensions.

Barclays analyst Alex Scott maintains Corebridge Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) with a Overweight and lowers the price target from $37 to $36.

CRBG

Barclays Maintains Overweight on Corebridge Financial, Lowers Price Target to $36

Barclays analyst Alex Scott maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Overweight and lowers the price target from $324 to $321.

Barclays Maintains Overweight on Chubb, Lowers Price Target to $321

Barclays analyst Alex Scott maintains Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) with a Equal-Weight and raises the price target from $119 to $121.

Barclays Maintains Equal-Weight on Brown & Brown, Raises Price Target to $121

Barclays analyst Alex Scott maintains Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) with a Equal-Weight and raises the price target from $308 to $346.

Barclays Maintains Equal-Weight on Arthur J. Gallagher, Raises Price Target to $346

Truist Securities analyst William Stein initiated coverage on MACOM Technology Solutions Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) with a Buy rating and a <a href="https://www.benzinga.com/quote/MTSI/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $125 on Friday</a>.
MACOM Technology is one of the largest suppliers of radio frequency (RF) and similar components. Stein noted that this mature, cyclical, innovative industry is growing at 5% annually.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44653936/broadcom-and-marvell-poised-for-growth-as-nvidias-cpo-push-faces-delays-analyst-reveals" rel="noreferrer noopener">Rising Tide Of AI Is So Strong That Semiconductor Optical Industry Projects $30 Billion Total Addressable Market By 2029</a>
MACOM Technology serves the defense, industrial, data center (AI) and telco end markets (with no consumer exposure). Recently, acquisitions have boosted MACOM Technology&#8217;s financial metrics, including revenue growth (above industry), EPS, and ROIC (above WACC). Stein expects this dynamic will continue in the future.
The most prominent is an AI-linked theme: optical components used in data center communications (growing 27% in the medium term). A more overlooked growth driver is components for low-earth orbit (LEO) commercial satellites (growing 68% in the medium term). A third driver is MACOM Technology&#8217;s extending its GaN-on-SiC semiconductor technology from the telco end market into the industrial, defense, and data center end markets (growing 18% in the medium term).
Stein expects these drivers to lift MACOM Technology&#8217;s medium-term growth by about 12%.
A significant part of MACOM Technology&#8217;s heritage business, including industrial and parts of telco, is cyclically depressed, down about 40% from its peak level. Stein expects these will recover over the next few years, which should boost MACOM Technology&#8217;s medium-term growth by about 3%.
Tariffs create more than typical volatility around unit demand, costs, and pricing. MACOM Technology will be affected, but Stein noted the effects will be somewhat more moderate than average, considering its geographic split of revenue and manufacturing.
If not for tariffs, Stein would have established a more optimistic model, including over $5 of EPS in calendar 2026; however, tariffs brought him to a more conservative result. Stein&#8217;s base case expectation is for MACOM Technology to deliver calendar 2026 revenue of $1.06 billion and EPS of $4.46. He projected calendar 2025 revenue of $960 million and EPS of $3.66.
The company historically trades at a five times premium to the peer group, which trades at 23 times. This suggests a 28 times P/E. 
MTSI Price Action: MTSI stock is up 0.15% at $99.42 at publication on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42953261/nvidia-broadcom-and-marvell-positioned-for-growth-as-ai-demand-drives-semiconductor-momentum" target="_blank" rel="noreferrer noopener">Nvidia, Broadcom, Marvell Positioned For Growth As AI Demand Drives Semiconductor Momentum</a></li>
</ul>
Photo: Goran Gjorovski via Shutterstock

SPACE

Initiation

Tech

MTSI

Truist Securities Bullish As MACOM Technology Taps AI, Satellites For Next Wave Of Growth

Cryptocurrency markets are trading higher on Friday, amid Florida passing a Bitcoin reserve bill.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$83,687.73</td>
<td>+5.5%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$1,565.31</td>
<td>+3.3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$120.10</td>
<td>+8.4%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.03</td>
<td>+4.3%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1599</td>
<td>+4.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001220</td>
<td>+5.7%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 12.3% and daily active addresses grow ingby 5.6%. Transactions greater than $100,000 are down from 11,411 to 10,6343 in a single day. Exchanges netflows are down by 467.5%.</li>
<li>Coinglass data reports 98,702 traders were liquidated in the past 24 hours for $242.45 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/top-stories/25/04/44758705/ripple-sec-move-to-end-legal-dispute-as-both-sides-withdraw-appeals">Ripple, SEC Move To End Legal Dispute As Both Sides Withdraw Appeals</a></li>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44764584/solana-jumps-as-janover-adds-5m-to-treasury-strategy-doubling-down-on-crypto-pivot">Solana Jumps As Janover Adds $5M To Treasury Strategy, Doubling Down On Crypto Pivot</a></li>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44764578/why-is-bitcoin-up-today-btc-climbs-past-83k-as-florida-passes-historic-bitcoin-reserve-bill">Why Is Bitcoin Up Today? BTC Climbs Past $83K As Florida Passes Historic Bitcoin Reserve Bill</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44747802/block-fined-40-million-by-new-york-regulator-over-cash-app-compliance-failures">Block Fined $40 Million By New York Regulator Over Cash App Compliance Failures</a></li>
</ul>
 Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Onyxcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">XCN</a>)</td>
<td>$0.02533</td>
<td>+53.4%</td>
</tr>
<tr>
<td>Fartcoin (CRYPTO: FARTCOIN)</td>
<td>$0.9031</td>
<td>+29.7%</td>
</tr>
<tr>
<td>AB (CRYPTO: AB)</td>
<td>$0.01340</td>
<td>+24.2%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto traders are watching Bitcoin's price action closely as it attempts to break free from a persistent downtrend—and many believe this time could be different. 
Jelle highlighted that Bitcoin is trying to break out of a downtrend it&#8217;s failed to escape seven times before. The big question: will bulls finally push through the $84,000 resistance?
Ali Martinez raised caution, asking whether Bitcoin&#8217;s recent bounce was the completion of a W pattern, and if so, is an M pattern, a bearish reversal on deck?
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If the first <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> move up was a &quot;W,&quot; are we about to see an &quot;M&quot;? <a href="https://t.co/59QCxjev28">pic.twitter.com/59QCxjev28</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1910742138427760916?ref_src=twsrc%5Etfw">April 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Mayne noted that Bitcoin is testing a key 12-hour order block (H12 OB). A flip of this resistance into support could generate serious upside momentum, making for what he calls "a very fun weekend."
Rekt Capital emphasized that a true breakout isn't confirmed yet—Bitcoin needs a daily close above the downtrend and a successful retest to validate the move.
Meanwhile, Titan of Crypto spotted a potential Inverse Head &amp; Shoulders pattern playing out. If confirmed, the long-term measured move projects a target near $125,000 by 2025.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> Inverse Head &amp; Shoulders Pattern &#x1f9e0;&#x1f4c8; Still looks like a clean retest for now. If the pattern plays out, <a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> could reach $125,000 in 2025. Let's see. <a href="https://t.co/HvR0cdZYmM">pic.twitter.com/HvR0cdZYmM</a>
&mdash; Titan of Crypto (@Washigorira) <a href="https://twitter.com/Washigorira/status/1910760473378578662?ref_src=twsrc%5Etfw">April 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/04/44763111/rising-tariff-tensions-deepen-global-fragmentation-experts-say-bitcoin-and-stablecoins-gaining-strategic-importance">Bitcoin, Stablecoins Will Gain From Trade War, Experts Say: &#8216;The Map Is Being Redrawn&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XCN

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Rally And 'Could Be In For A Very Fun Weekend' If One Key Level Flips

According to data released Thursday by the Bureau of Labor Statistics, the annual inflation rate fell to 2.4% in March, the lowest level in six months, down from 2.8% in February and below <a target="_blank" href="https://www.benzinga.com/news/econ-s/25/04/44733390/march-inflation-rate-cools-far-more-than-expected-raises-hopes-for-near-term-fed-rate-cuts" rel="noreferrer noopener">economist expectations of 2.6%</a>.
On a monthly basis, the Consumer Price Index contracted by 0.1%, slowing from the 0.2% increase seen the previous month and below expectations of a 0.1% increase.
It marks the lowest monthly inflation reading since May 2020.
Wedbush analyst writes that the tariff disaster Trump triggered last week has been weighing heavily on the stock market, creating <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">uncertainty and dragging down prices</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertainties" rel="noreferrer noopener">Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties</a>
Until now, it&#8217;s mostly been a Wall Street issue—but that&#8217;s about to shift. With the new 145% tariff on Chinese goods now in effect, U.S. consumers and businesses will feel the impact in the <a target="_blank" href="https://www.benzinga.com/markets/25/04/44751289/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">coming days and weeks</a>.
DA Davidson says that inflation dropping below 3% is generally a good sign, but what&#8217;s more important is why it&#8217;s happening. In other words, did inflation cool down in March because the economy is starting to slow?
&#8220;Although falling inflation should give the Fed more room on interest rate policy following stagflation worries, but may be at the whims of uncertain tariff policy,&#8221; DA Davidson analyst Michael Baker wrote.
Wedbush highlights Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is at the center of this tariff storm since 90% of iPhones are made in China. Although Apple has expanded its supply chain to places like Vietnam, India, and the U.S., most of its production still happens in Asia.
Wedbush estimates that most iPhones, over half of Mac products, and 75%–80% of iPads are made in China. If the tariffs last a few weeks, the company might raise iPhone prices to over $2,000.
Wedbush analyst on Tuesday said that building a factory in the U.S. takes four to five years. The analyst explains that high labor costs and other expenses in the U.S. don&#8217;t align with how modern supply chains are designed to operate, making it hard to compete with <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">Chinese tech giants</a>.
Wedbush analyst Daniel Ives writes, &#8220;We are heading into a very bumpy period as we expect a tech earning season that will be full of uncertainty, lack of guidance from many tech/China exposed tech players, and investors will need to buckle the seat belt and look past the next few quarters of choppiness and hold the tech winners through the storm.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44766429/trumps-tarifflation-in-the-spotlight-as-markets-shrug-off-cool-inflation-data-economist-says" target="_blank" rel="noreferrer noopener">Trump&#8217;s &#8216;Tarifflation&#8217; In The Spotlight As Markets Shrug Off Cool Inflation Data, Economist Says</a></li>
</ul>
Image via Shutterstock

Government

Large Cap

AAPL

Inflation Might Be Easing But Tech Outlook Still Choppy, Analysts Warn

Morgan Stanley analyst Kristine T Liwag downgraded Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) from Over-Weight to Equal-Weight rating and cut the <a target="_blank" href="https://www.benzinga.com/quote/JOBY/analyst-ratings" rel="noreferrer noopener">price forecast from $10 to $7</a>.
The aerospace industry, with its intricate global supply chains, faces heightened disruption risks from tariffs, especially given Boeing's ongoing challenges and lingering COVID-19 impacts.
The downgrade reflects the broader macroeconomic outlook presented by the MS US Economics team, which suggests that recent trade policy developments could significantly hinder economic growth.
Furthermore, the MS US Equity Strategy team has pointed out the potential second-order effects of tariffs, which may dampen corporate sentiment and further slow growth.
Given these conditions, the analyst does not anticipate that Joby's shares will outperform in a slower-growth, risk-averse environment.
Nonetheless, Liwag continues to view the long-term prospects for the eVTOL sector positively and sees Joby's advancements toward aircraft certification as encouraging.
The analyst estimates an EPS loss of 18 cents in the first quarter of 2025 and 73 cents for the year.
Price Action: JOBY shares are down 2.99% at $5.84 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44418300/joby-archer-navigate-evtol-uncertainty-as-faa-delays-market-shifts-persist" target="_blank" rel="noreferrer noopener">Joby, Archer Navigate eVTOL Uncertainty As FAA Delays, Market Shifts Persist</a></li>
</ul>
Image: Shutterstock

Mid Cap

Downgrades

Movers

JOBY

Joby Aviation Not Expected To Outperform As Tariffs, Trade Tensions Cloud Aerospace Outlook

<a href="https://t.co/3rV9Eoehdf" title="https://t.co/3rV9Eoehdf">https://t.co/3rV9Eoehdf</a> <a href="https://t.co/mRoun7JMp0" title="https://t.co/mRoun7JMp0">https://t.co/mRoun7JMp0</a>

PRSO

Peraso Receives Notice Of Allowance For A US Patent Titled "System For Seamless Recovery Of Distributed Access Points In A Wireless Local Area Network"

Omeros Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros&#8217; OncotoX biologics program focused on <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">acute myeloid leukemia (AML)</a>.
AML is the most fatal form of leukemia. It accounts for approximately 80% of acute leukemias in adults and one-third of all cancers <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44733942/omeros-announces-the-omeros-oncology-clinical-steering-committee-for-aml-to-help-guide-omeros-prop" rel="noreferrer noopener">affecting the blood/bone marrow</a>.
Omeros&#8217; OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the cancer cells, thereby killing them.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42598739/omeros-antibody-improves-overall-survival-in-rare-complication-after-stem-cell-transplant-stock-surges" rel="noreferrer noopener">Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges</a>
The steering committee will assist Omeros with developing the OncotoX-AML program, designing clinical trials, and interacting with institutional review boards, and it will also participate in OncotoX-AML clinical trials.
In vivo&nbsp;and&nbsp;ex vivo&nbsp;studies have shown that the OncotoX-AML therapeutic is highly effective even at very low doses, providing a significant survival benefit over currently approved combination therapy, like AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Genentech&#8217;s Venclexta (venetoclax) and Bristol Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Vidaza azacitidine).
In studies using primary AML derived from patients, the OncotoX molecule preferentially and efficiently kills AML blasts (abnormal myeloid cells).
OncotoX-AML also targets leukemia stem cells (LSC), often refractory to chemotherapy.
The OncotoX-AML therapeutic is designed specifically to kill both AML blasts and LSCs that can lead to relapse.
Preliminary&nbsp;in vivo&nbsp;tolerability studies demonstrate that the OncotoX therapeutic is well tolerated at doses substantially greater than one order of magnitude above efficacious doses without causing neutropenia or meaningful changes in blood chemistry values.
Omeros is initiating IND-enabling work for its OncotoX-AML therapeutic.
D. Boral analyst Jason Kolbert writes, &#8220;This development is particularly important given the persistent challenges in AML treatment. Despite recent drug approvals, therapeutic options for AML remain limited, especially for patients who are elderly, relapse-prone, or harbor high-risk mutations.&#8221;
Kolbert adds that chemotherapy and existing antibody-drug conjugates often fail to provide durable responses due to narrow therapeutic indices and toxic side effects. By demonstrating high efficacy in preclinical models without significant toxicity, OncotoX-AML presents the potential to address long-standing gaps in AML care.
The analyst maintains a Buy rating on Omeros with <a target="_blank" href="https://www.benzinga.com/quote/OMER/analyst-ratings" rel="noreferrer noopener">a price target of $36</a> while modeling Omeros&#8217; lead therapy, narsoplimab.
In February, the company resubmitted biologics license application for narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Omeros expects the target date for FDA action under the Prescription Drug User Fee Act to be six months following the date of resubmission to the FDA, meaning, in this case, the PDUFA date would be<a href="https://www.benzinga.com/pressreleases/25/03/b44570592/omeros-corporation-reports-fourth-quarter-and-year-end-2024-financial-results" target="_blank" rel="noreferrer noopener"> September 2025</a>.
The company expects to submit our European marketing authorization application for narsoplimab in TA-TMA in the first half of 2025.&nbsp;
Price Action: OMER stock is up 13.2% at $6.64 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44770461/intel-on-slump-as-china-hits-us-made-chips-with-tariffs-amd-and-taiwan-semiconductor-rise-on-exemption-boost" target="_blank" rel="noreferrer noopener">China Hits US-Made Chips With Tariffs, But Those Outsourcing To Taiwan Semiconductor Exempt</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Analyst Color

Biotech

Health Care

ABBV

OMER

RHHBY

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Press Releases

HUMBL, Inc. Announces $2 Million Share Exchange Agreement and Strategic Partnership With NUBURU, Inc. to Accelerate Growth and Shareholder Value

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

NUBURU Takes Strategic Leap Forward: First Acquisition Step in Defense and Security Sector Completed

NUBURU Makes Strategic Move into Defense Market with Groundbreaking Acquisition

Coeptis (NASDAQ: COEP) Accelerates Growth with Strategic Partnerships and Innovation

NUBURU Announces Elimination of 100% of its Long-Term Indebtedness and $5.15 Million Strategic Investment in Supply@ME Capital

NUBURU Advances Joint Development Agreement to Innovate Laser Applications in Defense Sector

NUBURU's (BURU) Strategic Leap: Expanding into Defense Technology with Innovative Laser Solutions

Comments

Nuburu

Vendite allo scoperto

Nuburu (AMEX:BURU) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO